Patents Assigned to Richter Gedeon Nyrt.
  • Patent number: 11298363
    Abstract: The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof which are centrally and/or peripherally acting V1a receptor modulators, particularly V1a receptor antagonists. Additional subject of the present invention is the process for the preparation of the compounds and the intermediates of the preparation process as well. The invention also relates to the pharmaceutical compositions containing the compounds or together with one or more other active substances, as well as to the use in the treatment and/or prophylaxis of a disease or condition associated with V1a receptor function.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 12, 2022
    Assignee: RICHTER GEDEON NYRT.
    Inventors: Ferenc Baska, Éva Bozó, Imre Bata, Krisztina Szondiné Kordás, Krisztina Vukics
  • Patent number: 11274119
    Abstract: The invention relates to the last step of a synthetic process, in which Nomegestrol-acetate of formula (I) is synthesized from 17?-acetoxy-6-methylene-19-norpregn-4-ene-3,20-dione of formula (II) in the presence of Pd/C catalyst and acetic acid in hot ethanolic solution.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 15, 2022
    Assignee: Richter Gedeon Nyrt.
    Inventors: Sándor Mahó, János Csörgei, Csaba Sánta, Péter Vincze, László Balogh, János Horváth, Zoltán Béni
  • Patent number: 11091436
    Abstract: The subject-matter of the invention is process for the separation of optical isomers of racemic 3-alk-3-carboxylic acid ethyl esters of formula rac-I with the resolving agent (II) (?)-2,3:4,5-di-O-izopropylidene-2-keto-L-gulonic acid (hereinafter: diacetone-L-ketogulonic acid).
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: August 17, 2021
    Assignee: RICHTER GEDEON NYRT.
    Inventors: Ferenc Faigl, Béla Mátravölgyi, Ágnes Mizsák
  • Patent number: 11026946
    Abstract: The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention al so relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention al so provides a method for manufacture of medicaments useful in the treatment of such disorders.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 8, 2021
    Assignee: RICHTER GEDEON NYRT.
    Inventors: István Borza, Viktor Román, János Éles, Zsuzsa Hadady
  • Patent number: 10960007
    Abstract: The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 30, 2021
    Assignee: RICHTER GEDEON NYRT.
    Inventors: István Borza, Viktor Román, János Éles, Zsuzsa Hadady, József Huszár
  • Patent number: 10660789
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 26, 2020
    Assignee: RICHTER GEDEON NYRT.
    Inventors: Ferenc Fülöp, László Vígh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
  • Patent number: 10487138
    Abstract: The present invention relates to the purification of immunoglobulins and the problem of providing a method for purifying an immunoglobulin in an efficient and cost-effective manner and with satisfactory purity and yield. In particular, the present invention addresses the aspect of the re-use of the rather cost-intensive chromatography materials, in particular the lifetime of the chromatography materials used in the capture step of the downstream process, and how this can be increased while reducing the technical complexity of the purification process.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: November 26, 2019
    Assignee: RICHTER GEDEON NYRT.
    Inventors: Ferenc Felföldi, Zsuzsa Benkö, Melinda Gáspár
  • Patent number: 10329296
    Abstract: The present invention relates to compounds of the general form (I). The present invention relates to new substituted diazepino-indole derivatives of the general formula (I), and to pharmaceutically acceptable salts thereof, as well as to pharmaceutical compositions comprising such compounds, to new intermediate thereof, as well as to the use of such compounds in treatment or prevention of disorders associated with melanin-concentrating hormone receptor 1 activity.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: June 25, 2019
    Assignee: Richter Gedeon NYRT.
    Inventors: Gyula Beke, János Éles, András Boros, Sándor Farkas, György Miklós Keserü
  • Patent number: 10258498
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: April 16, 2019
    Assignee: Richter Gedeon NYRT.
    Inventors: Ferenc Fülöp, László Vigh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
  • Patent number: 9994525
    Abstract: The present invention relates to new histamine H3 (H3) receptor subtype selective ligands of the general formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and the use of these compounds as medicaments for treatment and/or prevention of conditions which require modulation of H3 receptors. The invention also cover the combinations of a compound of the general formula (I) and an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: June 12, 2018
    Assignee: Richter Gedeon Nyrt.
    Inventors: Gizella Bartáné Szalai, Gäbor András Wágner, Béla Kiss, Éva Schmidt, Ottília Balázs, Noémi Nagy
  • Patent number: 9717691
    Abstract: The present invention relates to a medicament in the form of daily units, which contain an active ingredient combination consisting of a hormone combination with contraceptive action consisting of at least one oestrogen selected from the group consisting of estradiol and ethinyl estradiol and at least one gestagen selected from the group consisting of chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-acetoxy-chlormadinone acetate and 3-?-acetoxy-chlormadinone acetate, and at least one insulin sensitiser and which are combined to provide a dosage form with daily units which only contain an insulin sensitiser as the sole active ingredient, and to the use of this dosage form for preventing or treating pathological disorders caused by polycystic ovary syndrome (PCOS) and for simultaneous contraception.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: August 1, 2017
    Assignee: RICHTER GEDEON NYRT.
    Inventor: Georg Schramm
  • Patent number: 9683010
    Abstract: The present invention relates to a process for the synthesis of compounds of formula (I), wherein the meaning of R is dimethylamino or acetyl group, using the compound of formula (III) or (IV), wherein the meaning of R? is dimethylamino or 2-methyl-1,3-dioxan-2-yl group, as starting material and methoxymethyl lithium as reagent.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: June 20, 2017
    Assignee: Richter Gedeon Nyrt.
    Inventors: Sándor Mahó, Csaba Sánta, János Csörgei, Gábor Szabó, Tamás Schäfer, Zoltán Béni
  • Patent number: 9676814
    Abstract: The present invention relates to a new process for the synthesis of compounds of formula (I) (wherein the meaning of R is dimethylamino or acetyl group) using the compound of formula (II) (wherein the meaning of R is dimethylamino or 2-methyl-1,3-dioxolan-2-yl group) as starting material, as well as to the intermediate of the process.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: June 13, 2017
    Assignee: RICHTER GEDEON NYRT.
    Inventors: Sándor Mahó, Csaba Sánta, János Csörgei, János Horváth, Antal Aranyi, Zoltán Béni
  • Patent number: 9562067
    Abstract: The present invention relates to a new stereoselective process for the synthesis of 17(?)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(?)-17-acetyl-17-hydroxy-estr-4-en-3-one (gestonorone) is an important intermediate in the synthesis of the active ingredients having progestogen activity—such as gestonorone capronate and nomegestroi acetate. Formulas (I), (II) and (III).
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: February 7, 2017
    Assignee: RICHTER GEDEON NYRT.
    Inventors: János Csörgei, Anita Horváth, Csaba Sánta, Sándor Mahó, Zoltán Béni, János Horváth
  • Publication number: 20160311849
    Abstract: The present invention relates to a new process for the synthesis of compounds of formula (I) (wherein the meaning of R is dimethylamino or acetyl group) using the compound of formula (II) (wherein the meaning of R is dimethylamino or 2-methyl-1,3-dioxolan-2-yl group) as starting material, as well as to the intermediate of the process.
    Type: Application
    Filed: October 1, 2014
    Publication date: October 27, 2016
    Applicant: RICHTER GEDEON NYRT.
    Inventors: Sándor MAHÓ, Csaba SÁNTA, János CSÖRGEI, János HORVÁTH, Antal ARANYI, Zoltán BÉNI
  • Patent number: 9458207
    Abstract: New methods for the refolding of recombinant granulocyte colony stimulating factor (G-CSF) from inclusion bodies are disclosed. The methods comprise two refolding steps. In particular, the methods comprise the solubilizing of G-CSF with a solubilizing agent, the oxidative refolding (first refolding step) of G-CSF in the presence of the solubilizing agent and an oxidizing agent, the efficient removal of the solubilizing agent, and a second refolding step to complete the folding of G-CSF in the absence of the solubilizing agent. Various methods are described for the efficient removal of the solubilizing agent from partially refolded G-CSF.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 4, 2016
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ferenc Felföldi, Andras Ballagi, János Bécsi
  • Patent number: 9416164
    Abstract: New methods for the production of recombinant polypeptides from inclusion bodies are disclosed. Modulation of the cell culture conditions positively affects the yield of the recombinant polypeptide in active form. In one aspect, the methods comprise (a) cultivating a host cell at a first temperature, the host cell comprising a nucleic acid encoding a recombinant polypeptide, (b) lowering the cultivation temperature from the first temperature to a second temperature, and (c) cultivating the host cell at the second temperature.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: August 16, 2016
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ferenc Felföldi, Katalin Olasz, József Kozma
  • Patent number: 9278072
    Abstract: The present invention relates to a hormonal contraceptive including 21 to 25 hormone-containing daily units, which contain a combination of ethinyloestradiol in an amount of ?25 ?g and chlormadinone acetate in an amount of ?5 mg, and optionally 7 to 3 hormone-free daily units for oral administration to women.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: March 8, 2016
    Assignee: Richter Gedeon Nyrt.
    Inventors: Janine Klose, Johannes Bartholomäus, Klaus-Michael Wilsmann, Georg Schramm
  • Patent number: RE47333
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 2, 2019
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
  • Patent number: RE47350
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 16, 2019
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry